Salicylates, a class of NSAIDs, stop vestibular schwannomas growth
(Massachusetts Eye and Ear Infirmary) Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
CONCLUSION: In summary, we found a significant association between a larger Pt decline and a reduced risk of second cancers and deterioration of paresthesias in hands and tinnitus. PMID: 29775128 [PubMed - as supplied by publisher]
Massachusetts Eye and Ear researchers hope to launch mid-stage trials of a drug commonly used to induce chemical abortion, called mifepristone, to treat a rare type of brain tumor. Researchers had been looking for a drug to treat the growth of a potentially lethal brain tumor called vestibular schwannoma. The cancer usually causes hearing loss and tinnitus, but can also cause dizziness and facial nerve paralysis. Because of where such tumors grow – often on the vestibular, or balance, nerve —…
(Massachusetts Eye and Ear Infirmary) Massachusetts Eye and Ear researchers have shown that mifepristone, a drug currently FDA-approved for chemical abortion, prevents the growth of vestibular schwannoma (also known as acoustic neuroma) cells. This sometimes-lethal intracranial tumor typically causes hearing loss and tinnitus. The findings, published online today in Scientific Reports, suggest that mifepristone is a promising drug candidate to be repositioned for the treatment of these tumors.
This study used information from the VETSNET file, which is a snapshot of selected items from the Veterans Benefits Administration corporate database. We also used the National Death Index (NDI) for Veterans which is part of the VA Suicide Data Repository. In VETSNET, there were 758,324 Veterans who had a service-connected condition and died between the years 2004 and 2014. Using the scrambled social security number to link the two files resulted in 605,493 (80%) deceased Veterans. Age at death, sex, and underlying cause of death were obtained from the NDI for Veterans and military service characteristics and types of disa...
Products on well-understood commercialization tracks often take an incremental approach rather than trying to create paradigm-shifting technologies. In this blog, I’ll take a look at medical devices that are on a commercialization track to heal the patient of tomorrow in a way that is substantially better than previous offerings. They are generally broken into three broad categories based on their advantages over existing medical devices: either healing the patient at home, fixing issues with existing devices, or creating non-invasive diagnostic tools. Connected Home Use Devices Connected home-use devices allow a pat...
The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy.
The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. While associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy.
CONCLUSION: Pantoprazole did not ameliorate cisplatin ototoxicity or nephrotoxicity. The decrease in GFRcysC and increase in N-acetyl-ß-glucosaminidase (NAG) and creatinine demonstrate that these biomarkers can quantify cisplatin glomerular and proximal tubular toxicity. OCT2 inhibition by pantoprazole did not appear to alter antitumor response or survival. PMID: 29445029 [PubMed - as supplied by publisher]
CONCLUSION: Proton beam therapy is an effective and well-tolerated treatment modality of skull base paragangliomas, with documented functional benefit. A longer follow-up is planned in order to assess local control and long-term toxicities. PMID: 29269165 [PubMed - as supplied by publisher]
Researchers have developed a method to integrate functional MR (fMRI) and PET...Read more on AuntMinnie.comRelated Reading: PET/MRI outclasses MRI alone for pelvic cancer recurrence fMRI helps guide therapy designed to reduce tinnitus Researchers resolve PET/MRI issue for epilepsy patients PET/MRI could help diagnose kidney transplant infection